+17.9%
ONDS vs MRNA
-13.3%
+31.2%
-97.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.5% | +0.7% | -1.3% | -0.6% |
| 7D | -5.0% | -8.2% | +3.2% | -4.1% |
| 30D | -25.6% | +125.6% | -151.1% | -40.1% |
| 3M | -22.1% | +197.1% | -219.2% | -42.4% |
| 6M | -27.6% | +148.5% | -176.1% | -44.1% |
| YTD | -25.7% | +363.3% | -389.0% | -52.0% |
| 1Y | +30.4% | +462.0% | -431.6% | -20.8% |
| 3Y | +695.0% | +26.9% | +668.0% | +548.8% |
| 5Y | -2.2% | -69.6% | +67.4% | -6.4% |
| All | +17.9% | -13.3% | +31.2% | -4.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling